Compare ResMed Inc. (RMD) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Western Alliance Bancorporation — how do they compare? ResMed Inc. trades at $194.34 (market cap $28.81B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: ResMed Inc. is far larger — about 3.3× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| RMD | WAL | |
|---|---|---|
Market Cap | $28.81B | $8.84B |
Sector | Health | Financials |
52-Week High | $293.73 | $96.08 |
52-Week Low | $182.82 | $66.70 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.43 and net income margin of 25.63%, supported by consistent quarterly earnings outperformance. Recent news highlights Q2 2026 earnings miss but positive corporate recognition and leadership appointments.
Outlook remains positive with analyst consensus price target of $90.67 suggesting 12% upside. Risks include negative operating cash flow and high interest expenses. The bullish analyst sentiment (79% buy ratings) contrasts with technical bearishness, indicating potential value opportunity if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
